156 Results for "

DOTA

" in MedChemExpress (MCE) Product Catalog:
Products (156)

156 Results for "DOTA" in MCE Product Catalog:

17
Vipivotide tetraxetan
Vipivotide tetraxetan
0 Images
17 Publications Verification
Cat. No.: HY-117410
CAS No.: 1702967-37-0
Purity:  99.46%
Synonyms: PSMA-617
Target:  

Drug-Linker Conjugates for ADC

Research Areas:  

Cancer

Vipivotide tetraxetan (PSMA-617) is a high potent prostate-specific membrane antigen (PSMA) inhibitor, with a Ki of 0.37 nM. Vipivotide tetraxetan (PSMA-617) is designed consisting of three components: the pharmacophore Glutamate-urea-Lysine, the chelator DOTA able to complex both 68Ga or 177Lu, and a linker connecting these two entities. Glutamate-urea-Lysine is the selective pharmacophore to bind to prostate specific membrane antigen.
4
DOTATATE
DOTATATE
0 Images
4 Cited Publications
Cat. No.: HY-106244
CAS No.: 177943-88-3
Purity:  99.95%
Synonyms: Oxodotreotide
Target:  

Radionuclide-Drug Conjugates (RDCs)

Research Areas:  

Cancer

DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
4
DOTATATE acetate
DOTATATE acetate
0 Images
4 Cited Publications
Cat. No.: HY-106244A
CAS No.: 177943-89-4
Purity:  99.82%
Synonyms: Oxodotreotide acetate
Target:  

Radionuclide-Drug Conjugates (RDCs)

Research Areas:  

Cancer

DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
4
CCZ01048 TFA
CCZ01048 TFA
0 Images
4 Cited Publications
Cat. No.: HY-P2336A
Target:  

Melanocortin Receptor

Research Areas:  

Cancer

CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma .
2
Maleimide-DOTA
Maleimide-DOTA
0 Images
2 Cited Publications
Cat. No.: HY-133540
CAS No.: 1006711-90-5
Purity:  99.63%
Synonyms: Maleimido-mono-amide-DOTA
Target:  

ADC Linkers

Research Areas:  

Inflammation/Immunology Cancer

Maleimide-DOTA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
2
DOTA-LM3
DOTA-LM3
0 Images
2 Cited Publications
Cat. No.: HY-P5126
CAS No.: 1192362-32-5
Target:  

Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor

Research Areas:  

Cancer

DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
2
DOTA-LM3 TFA
DOTA-LM3 TFA
0 Images
2 Cited Publications
Cat. No.: HY-P5126A
Target:  

Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor

Research Areas:  

Cancer

DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
2
Pentixafor
Pentixafor
0 Images
2 Cited Publications
Cat. No.: HY-153549
CAS No.: 1341207-62-2
Purity:  99.03%
Target:  

Radionuclide-Drug Conjugates (RDCs) CXCR

Research Areas:  

Others

Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with 68Gallium ( 68Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
1
DOTA-​NHS-ester
DOTA-​NHS-ester
0 Images
1 Cited Publications
Cat. No.: HY-128890
CAS No.: 170908-81-3
Purity:  ≥95.0%
Target:  

ADC Linkers

Research Areas:  

Cancer

DOTA-NHS-ester is a linker for affibody molecules and is applied in small animals PET, SPECT, and CT. DOTA-NHS-ester can be used to label radiotherapeutic agents or imaging probes for the detection of tumors .
1
p-SCN-Bn-DOTA
p-SCN-Bn-DOTA
0 Images
1 Cited Publications
Cat. No.: HY-114377
CAS No.: 127985-74-4
Purity:  99.78%
Target:  

Radionuclide-Drug Conjugates (RDCs)

Research Areas:  

Cancer

p-SCN-Bn-DOTA is a bifunctional chelating agent. p-SCN-Bn-DOTA can simultaneously chelate radionuclides and link monoclonal antibody for radioimmunoresearch of tumor .
1
Tetraxetan
Tetraxetan
0 Images
1 Cited Publications
Cat. No.: HY-W053583
CAS No.: 60239-18-1
Synonyms: DOTA
Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .
1
DOTA-JR11
DOTA-JR11
0 Images
1 Cited Publications
Cat. No.: HY-P5128
CAS No.: 1039726-31-2
Synonyms: Satoreotide tetraxetan
Target:  

Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor

Research Areas:  

Cancer

DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
1
DOTA-​NHS-ester TFA
DOTA-​NHS-ester TFA
0 Images
1 Cited Publications
Cat. No.: HY-128890B
Purity:  95.00%
Target:  

ADC Linkers Biochemical Assay Reagents

Research Areas:  

Cancer

DOTA-​NHS-ester (TFA) is used as a linker for affibody molecules, and it can be employed in small animal positron emission tomography (PET), single photon emission computed tomography (SPECT), and CT scanning. DOTA-​NHS-ester can be used to label radiotracers or imaging probes for tumor detection .
DOTA-tri(t-butyl ester)
DOTA-tri(t-butyl ester)
0 Images
Cat. No.: HY-W034551
CAS No.: 137076-54-1
Target:  

Radionuclide-Drug Conjugates (RDCs)

Research Areas:  

Others Cancer

DOTA-tri(t-butyl ester) belongs to the DOTA class of chelating agents. DOTA-tri(t-butyl ester) is a key raw material for synthesizing nanospherical magnetic resonance imaging (MRI) contrast agents, which are used in MR angiography and tumor angiogenesis imaging .
DOTA-tris(tBu)ester NHS ester
DOTA-tris(tBu)ester NHS ester
0 Images
Cat. No.: HY-131326
CAS No.: 819869-77-7
Purity:  ≥98.0%
Target:  

Biochemical Assay Reagents

Research Areas:  

Cancer

DOTA-tris(tBu)ester NHS ester is a bifunctional precursor to a DOTA-based chelating agent. DOTA-tris(tBu)ester NHS ester can be used to label primary amines (R-NH2) of proteins, amine-modified oligonucleotides, and other amine-containing molecules, and upon deprotection forms stable complexes with metal ions for applications in molecular imaging .
DOTAGA-anhydride
DOTAGA-anhydride
0 Images
Cat. No.: HY-W087187
CAS No.: 1375475-53-8
Target:  

Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents

Research Areas:  

Infection Cancer

DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride has been successfully used for labeling antibodies (e.g., Trastuzumab (HY-P9907)). DOTAGA-anhydride can be used for the synthesis of a bimodal tag for Single-photon emission computed tomography (SPECT) or PET/optical imaging .
DOTA-GA(tBu)4
DOTA-GA(tBu)4
0 Images
Cat. No.: HY-W614269
CAS No.: 306776-79-4
Target:  

Radionuclide-Drug Conjugates (RDCs)

Research Areas:  

Cancer

DOTA-GA(tBu)4 stabilizes the attachment of radiometals to ligands. DOTA-GA(tBu)4 improves the biodistribution of radiolabeled second-generation Affibody molecules by increasing their net negative charge and reducing hepatic uptake, leading to enhanced tumor-to-blood and tumor-to-liver ratios. DOTA-GA(tBu)4 targets HER2>-expressing breast and gastrointestinal cancer .
DOTA-GPC3 targeting peptide 2
DOTA-GPC3 targeting peptide 2
0 Images
Cat. No.: HY-W1124925
CAS No.: 3066439-94-6
Target:  

Radionuclide-Drug Conjugates (RDCs) Glycoprotein VI

Research Areas:  

Cancer

DOTA-GPC3 targeting peptide 2 (Sequence 30) is a RDC peptide targeting GPC3, with Kd of 0.3 nM. DOTA-GPC3 targeting peptide 2 is composed of DOTA and GPC3 targeting peptide 2. DOTA-GPC3 targeting peptide 2 can be labeled with radioactive elements .
NH2 DOTA-GA
NH2 DOTA-GA
0 Images
Cat. No.: HY-164569
CAS No.: 1639843-65-4
Target:  

Radionuclide-Drug Conjugates (RDCs)

Research Areas:  

Cancer

NH2 DOTA-GA is a DOTA-based metal chelator that can be used to prepare radionuclide drug conjugates (RDCs) whose carboxylic acid groups can complex metal ions, for example, NH2 DOTA-GA complexes Gd(III) ions.
(S)-p-SCN-Bn-DOTA
(S)-p-SCN-Bn-DOTA
0 Images
Cat. No.: HY-156038
CAS No.: 1020407-41-3
Purity:  99.75%
(S)-p-SCN-Bn-DOTA is a bifunctional chelator (BFC), a macrocyclic DOTA derivative for tumor pretargeting. (S)-p-SCN-Bn-DOTA can be used for the conjugation of peptides and radionuclides, such as as a linker for In-111 labeled radioimmunoconjugates (RICs) for single photon emission tomography (SPECT) and in vitro biodistribution studies .
Assay Types